[ad_1]
Carl Sterritt of Shield Therapeutics PLC (LON: STX) announced to Andrew Scott of Proactive London that they would continue to vigorously defend their intellectual property after being informed that Teva Pharmaceutical Industries Ltd had appealed the decision regarding the Feraccru treatment of STX.
"This drug is already well protected until 2029 with the basic manufacturing patent that has already been extended."
Feraccru is an oral treatment for iron deficiency, with or without anemia.
It is approved and marketed in Europe, with a US approval decision pending for July 27th.
Source link
